Summary:
A UK SME has developed novel wound diagnostic kits that detect elevated host protease activity (EPA) and bacterial protease activity (BPA) that enables a more effective treatment regime to be undertaken. The products offer significant potential savings for health services when this diagnostic capability is correctly implemented into their woundcare protocols. The company is looking for partners via a distribution services agreement within identified European markets.
Description:
This North of England SME was formed in order to improve therapeutic outcomes in wound healthcare. Ineffective wound care is estimated to cost health services $20-25bn annually. This novel product offers insight into the state of the wound so that the doctor can take the correct course of action. Elevated Protease Activity (EPA) and bacterial protease activity (BPA) are undetectable without testing and the tests take only fifteen minutes to obtain a result.
The product is CE marked and the company has evidence of effectiveness. The company is looking for distributors in European markets via a distribution services agreement.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company is ideally looking for a partner who supplies a range of diagnostic or wound care products into health services in their location and wishes to supply new products to their customer base
Area of activity - Supplier of diagnostic/wound care medical solutions
Task to be performed - understand where this product would be relevant and useful.
They have identified a select group of European markets to target. This will be via a distribution services agreement.
Stage of Development:
Already on the market
External code:
BOUK20210120002
